Kidney COP 120 Capsules, Patented Calcium Oxalate Kidney Support, Free Shipping!

Description: 99% Reduction in the Rate of Calcium Oxalate Stone Growth**Five Times (5X) More Powerful than Chanca Piedra 5:1 Extract ( a.k.a. Stone Breaker). Scientifically documented tests performed by Dr. James Murray, Dept of Chemistry, Immaculata College; February 2018. Study available upon request.Recommended by Medical Doctor Trained in UrologyInnovative Formulation Awarded Five (5) U. S. Patents***Utilizes a Patented, Delayed-Release Capsule Optimizing Absorption in the Intestines and Not the Stomach Product Description +Dr. Mathew Davis received his Medical Degree at the Drexel University, formerly the Medical College of Pennsylvania, in 1994. Dr Davis earned his undergraduate degree from the University of Pennsylvania. Dr. Davis also received his pharmacy degree at Temple University in 1989. Dr Davis has held high level clinical and research positions in several pharmaceutical companies including Dr. Reddy's Laboratories, Eisai, URL Pharma Inc, and Lupin. ++Three of Kidney C.O.P.’s five active ingredients are GRAS, the fourth is listed within National Institutes of Health, Office of Dietary Supplements Fact Sheet Magnesium along with recommended Daily Values and the fifth is ground Musa Paradisiaca (banana stems) a natural food consumed throughout the world. Government Documentation that is a GRAS Ingredient can be found in CFR Government Federal Code of Regulations Title 21 - Citric Acid | 21 CFR 184.1033 - Inositol (IP6) (Phytin) Phytic Acid | 21 CFR 184.1370 - Pyridoxine Hydrochloride | 21 CFR 184.1676 +++Manufacturer is located in Davie, Florida and has been certified by National Sanitation Foundation (NSF) International to comply with GMP (Good Manufacturing Practices). NSF International was founded in 1944 from the University of Michigan's School of Public Health as the National Sanitation Foundation (NSF) to standardize sanitation and food safety requirements. The recent GMP certification number is C0024494-CS-1 and is dated January 27, 2020. A copy of GMP certification is available upon request. ++++Each manufactured batch of Kidney C.O.P. is tested at Arnet Pharmaceutical located in Davie, Florida for product potency. Every batch tested for "potency" must surpass 100% of claim for every active ingredient or it cannot be released for encapsulation and bottling by Arnet Pharmaceutical. Kidney C.O.P. formulation is also tested for the long term stability of product potency for three years. Stability of a product means how long it can maintain its original form without any major changes under the influence various environmental factors like temperature, humidity, and light. For validating the long term stability and to be able to provide proper product expiration dating, the first three lots of Kidney C.O.P. (lot numbers 703885, 703886, and 703887) where tested for stability. Stability studies have passed for long term stability (3 years). The studies began in 04/2017, and finished in 04/2020. Lots were tested for stability at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, and 36 months. The most recent, 36 months stability testing conducted by Arnet Pharmaceutical, Davie Florida , received results during 05/2020. Copies of stability studies are available upon request. ------------------------ *These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. **Supporting studies and testing results documenting the 99% inhibition in the rate of calcium oxalate stone crystal growth can be found in the United States Patent 9,233,135, under Table 2 Labeled Data Analysis for Slope Test. Control Vehicle & Test Solution 1. ***US Patent Numbers: 9,233,135, / 9,492,491 / 9,623,006 / 9,789,152 / and 10,471,115. Most recent patent is dated February 20, 2020. ****Many of Kidney C.O.P.'s active ingredients (or combination of) have been tested in clinical studies & have shown to have an effect inhibiting calcium oxalate crystal growth. Many of these clinical studies are found in the five patents: 9,233,135; 9,492,491; 9,623,006; 9,789,152; 10,471,115 - pgs 1 - 3 of each patent. Just a few of these clinical studies are listed: J Altern Complement Med 2008 Dec;14(10):1287-90. doi: 10.1089/acm.2008.0189. A prospective, randomized, controlled study to evaluate the efficacy & tolerability of Ayurvedic formulation "varuna and banana stem" in the management of urinary stones. Patankar S1, Dobhada S, Bhansali M, Khaladkar S, Modi J. Br J Urol. 1991 Mar;67(3):237-40. Results of long-term rice bran (inositol hexaphosphate (IP6) treatment on stone recurrence in hypercalciuric patients. Ebisuno S1, Morimoto S, Yasukawa S, Ohkawa T. J Urol. 1997 Dec;158(6):2069-73. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Ettinger B1, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A., J Urol. 2009 Mar;181(3):1145-50. doi: 10.1016/j.juro.2008.11.014. 2009 Jan 18. Impact of long-term potassium citrate therapy on urinary profiles & recurrent stone formation. Effect of potassium citrate therapy on stone recurrence & residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial., Soygür T1, Akbay A, Küpeli S. ,J Endourol. 2002 Apr;16(3):149-52. The core of the pseudostem of musa in the treatment of urinary stones. R. Gopakumara Pillai Consultant Urologist, District Hospital, Kollam, Kerala, India., Ancient science of life 07/1995; 15(1):2-6., PubMed Int Urol Nephrol. 1988;20(4):353-9.Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Mitwalli A1, Ayiomamitis A, Grass L, Oreopoulos DG. Effect of daily MgO & vitamin B6 administration to patients with recurring calcium oxalate kidney stones. S N Gershoff, E L Prien. PMID: 6023850 DOI: 10.1093/ajcn/20.5.393

Price: 47.69 USD

Location: Denver, Colorado

End Time: 2024-10-01T01:35:47.000Z

Shipping Cost: 0 USD